Picture EBD Group Startup Spotlight at BIO-Europe 2023 650x100px

Document › Details

Silence Therapeutics plc. (7/3/17). "Press Release: Issue of Claim in the UK High Courts".

	Region	United Kingdom (GB)
	Organisation	Silence Therapeutics plc (Nasdaq: SLN)
	Group	Silence Therapeutics (Group)
	Organisation 2	Alnylam UK Ltd.
	Group	Alnylam (Group)
	Product	RNAi technology
	Product 2	RNAi drug (RNAi therapeutic)
	Person	Mortazavi, Ali (Silence Therapeutics 201305– CEO before Director of Corporate Strategy joined 2012)
	Person 2	Ellam, David (Juvenescence 201904– CFO before Silence Therapeutics + BioMarin + Plethora Solutions + Ark Therapeutics)

Silence Therapeutics plc, AIM:SLN (“Silence” or “the Company”) a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that it has today issued a claim in the UK High Courts of Justice (Patents Court) naming as defendants Alnylam UK Limited, Alnylam Pharmaceuticals Inc, and The Medicines Company UK Limited.

Silence has previously stated that it is committed to defending its Intellectual Property (IP) and to secure the appropriate value for this IP, it will act to enforce its patent estate as necessary. The claim asks the Court to determine whether Silence is entitled to “supplementary protection certificates” (SPCs) on several late stage Alnylam products, which include Patisiran, Fitusiran, Givosiran and Inclisiran (partnered with The Medicines Company), and could result in the extension of Silence’s European patent protection on these products. SPCs are intellectual property rights which can give up to 5 years of exclusivity after a patent expires. Separately, Silence is actively continuing to uphold its patent estate in other global regions.

Ali Mortazavi, Chief Executive Officer of Silence Therapeutics, commented:
“We reiterate, as stated in our press release on 30th May 2017, that we consider potential licences under our patent estate could have a significant financial effect relative to the current market capitalisation of Silence. As such, we consider the commencement of this process to be the next step in realising this value."

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

Enquiries:

Silence Therapeutics plc
Ali Mortazavi, Chief Executive Officer
David Ellam, Chief Financial Officer
Tel: +44 (0)20 3457 6900

Peel Hunt LLP (Nominated Adviser and Broker)
James Steel/Oliver Jackson
Tel: +44 (0)20 7418 8900

Media Enquiries:
FTI Consulting
Simon Conway/Brett Pollard/Stephanie Cuthbert
Tel: +44 (0) 20 3727 1000

Notes to Editors

About Silence Therapeutics plc

Silence Therapeutics develops a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence’s proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

Record changed: 2023-06-05